Dose Ranging Trial to Determine the Safety and Efficacy of EMA401 in Patients With PHN

Neuralgia, Postherpetic Clinical Trial

Official title:

A Double-blind, Placebo-controlled, Randomized Dose Ranging Trial to Determine the Safety and Efficacy of Two Dose Levels of EMA401 in Patients With Postherpetic Neuralgia

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02426411
• Other study ID #: EMA401-006
• Status: Withdrawn
• Phase: Phase 2
• First received: April 17, 2015
• Last updated: August 25, 2015
• Start date: June 2015
• Est. completion date: December 2016

Study information

• Verified date: August 2015
• Source: Spinifex Pharmaceuticals Pty Ltd
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Food and Drug AdministrationGermany: Federal Institute for Drugs and Medical DevicesUnited Kingdom: Medicines and Healthcare Products Regulatory AgencyBulgaria: Bulgarian Drug AgencySouth Africa: Human Research Ethics Committee
• Study type: Interventional

Clinical Trial Summary

The study is a randomized, double blind, placebo-controlled, parallel-group comparison (two dose levels of EMA401 versus a placebo group), of safety and efficacy in patients with postherpetic neuralgia.

Description:

Screening Period (Up to Four Weeks) to confirm eligibility for the study which will be determined by Screening tests, physical examination/medical history and fulfillment of eligibility criteria including assessment of pain.

Study Period (14 Weeks) Approximately 360 eligible male and female patients will receive double-blind treatment for 14 weeks. Patients will be randomized in a 1:1:1 ratio to treatment with EMA401 100 mg BID, 300 mg BID or placebo.

Patients will attend the study site at the end of the Baseline visit and end of Weeks 1, 3, 5, 7, 9, 11, 13, and 14 for on-study assessments.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 2016
• Est. primary completion date: October 2016
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Be diagnosed as suffering from PHN defined as pain in the region of the rash persisting for more than six months after onset of herpes zoster rash.

• Be assessed as suffering from moderate to severe pain across the Screening Period. The assessment of moderate and severe pain will be made using an algorithm proprietary to Spinifex. The Investigator/site staff will be informed immediately as to whether the patient is eligible or ineligible on the ePRO website based on the patient entering all relevant pain scores in the eDiary device.

• Women of child bearing potential (WOCBP) must have a negative urine pregnancy test at the Screening Visit (Visit 1) and within 72 hours prior to administration of IP.

Exclusion Criteria:

• Patients taking any topical treatment for their PHN at the time of Screening Visit 2 will be excluded, including lidocaine plaster, capsaicin patch, and any other topical preparations of these or any other topical medications (e.g., aspirin, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)) for their PHN.

• Have a blood pressure reading, after resting for at least five minutes, outside a systolic blood pressure range of 84-151 mmHg or a diastolic blood pressure > 95 mmHg. If the blood pressure is outside of the range, a repeat measurement can be taken after the patient has rested. The repeat measurement should be used as the screening value.

• Have serum aspartate transaminase (AST) or alanine transaminase (ALT) levels > 1.5 x the upper limit of normal or have total bilirubin concentrations > 1.5 x the upper limit of normal at Screening (Visit 1).

• Patients who have a known diagnosis of diabetes and are stable on medication with a hemoglobin A1c > 8%. Those who do not have a known diagnosis of diabetes with a hemoglobin A1c > 7%.

• Have active herpes zoster upon physical examination at Screening (Visit 1) or during the study.

• Known history of, or positive laboratory result for hepatitis B virus (HBV), hepatitis C virus (HCV) or human immunodeficiency virus (HIV) infection as defined by being seropositive for hepatitis B surface antigen (HBsAg), HCV antibodies or HIV antibodies respectively.

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Neuralgia
• Neuralgia, Postherpetic

Intervention

Drug:
• EMA401 200 mg

• EMA401 600 mg

• Placebo

Locations

Country	Name	City	State
n/a

Sponsors (2)

Lead Sponsor	Collaborator
Spinifex Pharmaceuticals Pty Ltd	INC Research

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To determine the efficacy of two dose levels of EMA401 compared to placebo in patients with postherpetic neuralgia (PHN), as assessed by the change in the weekly mean of the 24 hour average pain score using an 11-point Numerical Rating Scale (NRS)		Baseline to approximately Week 14	No
Secondary	To evaluate the effect of EMA401 compared to placebo on the Brief Pain Inventory-Short Form (BPI-SF) interference total score		Baseline to approximately Week 14	No
Secondary	To evaluate the effect of EMA401 compared to placebo on the weekly mean of the 24 hour worst NRS pain score		Baseline to approximately Week 14	No
Secondary	To evaluate the effect of EMA401 compared to placebo on the Patient Global Impression of Change (PGIC)		Baseline to approximately Week 14	No
Secondary	To evaluate the effect of EMA401 compared to placebo on the BPI-SF average pain		Baseline to approximately Week 14	No
Secondary	To determine the proportion of EMA401 patients achieving a = 30% and a = 50% reduction in weekly mean pain of the 24 hour average score (NRS) compared to placebo (i.e., responder rates)		Baseline to approximately Week 14	No
Secondary	To evaluate the effect of EMA401 compared to placebo on the Insomnia Severity Index (ISI)		Baseline to approximately Week 14	No
Secondary	To evaluate the safety and tolerability of EMA401 in patients with PHN as measured by adverse events, vital signs, and laboratory results		Baseline to approximately Week 14	Yes